How long can Pertuzumab be used?

When Pertuzumab and trastuzumab are used to treat HER2+ early-stage breast cancer as adjuvant therapy (after cancer surgery), the combination regimen can be continued every 3 weeks for one year (up to 18 cycles), but doctors will remind patients that treatment may need to be stopped early due to side effects or if the breast cancer recurs.

When pertuzumab is given as neoadjuvant therapy (before surgical treatment for HER2+ early-stage breast cancer), patients will receive pertuzumab, trastuzumab, and chemotherapy every 3 weeks for 3-6 cycles. If patients start pertuzumab and trastuzumab-based therapy before surgery, they may continue treatment after surgery until they have completed approximately 1 year (a total of 18 cycles). For treatment of HER2+ metastatic breast cancer, patients will receive pertuzumab and trastuzumab until the drug no longer controls the breast cancer or the patient develops side effects from the drug that require discontinuation of treatment.

Pertuzumab is a strictly controlled drug. The original drug has been marketed in China and has entered the ranks of medical insurance, but it is only reimbursed for patients who meet the indications. The price of each box may be more than more than 5,000 yuan, and the price of the Hong Kong version may be more than 20,000 yuan (the price may fluctuate due to exchange rates). The price of each box of the European version of Pertuzumab's original drug marketed overseas may be more than 10,000 yuan, and the price of each box of the Turkish version may be more than 6,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the domestic and foreign original drugs are basically the same, and there are currently no generic versions of Pertuzumab on the market.